

STATE OF MICHIGAN
DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS
BUREAU OF PROFESSIONAL LICENSING
BOARD OF NURSING
DISCIPLINARY SUBCOMMITTEE

In the Matter of

JENNIFER ANNE-CISCO EIFLER, R.N., C.N.M.

License No. 47-04-271973,

Respondent.

File No. 47-23-001834

ADMINISTRATIVE COMPLAINT

The Michigan Department of Licensing and Regulatory Affairs, Bureau of Professional Licensing, complains against Respondent as follows:

1. The Michigan Board of Nursing is an administrative agency established by the Public Health Code, MCL 333.1101 *et seq.* Pursuant to MCL 333.16226, the Board's Disciplinary Subcommittee (DSC) is empowered to discipline licensees for violations of the Public Health Code.

2. Respondent holds a Michigan license to practice as a registered nurse and holds a specialty certification as a nurse midwife. Respondent also holds an active drug control license.

3. At all relevant times, Respondent was employed as a nurse at Planned Parenthood located in Detroit, Michigan.

4. Benzocaine (e.g., Vagisil) is a local anesthetic, numbing medication. It works by blocking nerve signals in the body.

5. Lidocaine is a local anesthetic, numbing medication. It is used to numb an area of the body to help reduce pain and discomfort.

6. Epinephrine is used to treat serious allergic reactions.
7. Resorcinol (e.g., Resinol) works to break down rough or hardened skin and also disinfects the skin to help fight infection.
8. On or about April 12, 2023, Respondent was found to have a non-approved medical cream in her procedure caddy at work.
9. Staff learned from Respondent that the cream was homemade from over-the-counter medications such as benzocaine, lidocaine, epinephrine, and resorcinol. Respondent admitted to using the cream on one patient without a physician's order.
10. Management stated that all medications used on patients in the clinic are pre-approved by Planned Parenthood and obtained from approved vendors.
11. Respondent's employment was subsequently terminated.
12. In an email with a Department investigator, Respondent stated that she had made an error in judgment and that using her homemade cream without proper testing was a bad idea.

COUNT I

Respondent's conduct as set forth above, constitutes a violation of a general duty, consisting of negligence or failure to exercise due care, including negligent delegation to or supervision of employees or other individuals, or a condition, conduct, or practice that impairs, or may impair, the ability safely and skillfully to engage in the practice of the health profession in violation of MCL 333.16221(a).

COUNT II

Respondent's conduct, as set forth above, demonstrates Respondent's "departure from, or failure to conform to, minimal standards of acceptable and prevailing practice for the health profession, whether or not actual injury to an individual occurs," and accordingly "incompetence," in violation of MCL 333.16221(b)(i).


COUNT III

Respondent's conduct, as set forth above, demonstrates Respondent's practicing outside the scope of her license, in violation of MCL 333.16221(c)(iii).

RESPONDENT IS NOTIFIED that, pursuant to MCL 333.16231(8), Respondent has 30 days from the date of receipt of this Complaint to submit a written response to the allegations contained in it. Pursuant to MCL 333.16192(2), Respondent is deemed to be in receipt of the complaint three (3) days after the date of mailing listed in the attached proof of service. The written response shall be submitted by email to the Department of Licensing and Regulatory Affairs, Bureau of Professional Licensing to LARA-BPL-RegulationSection@michigan.gov . If unable to submit a response by email, Respondent may submit by regular mail to the **Department of Licensing and Regulatory Affairs, Bureau of Professional Licensing, P.O. Box 30670, Lansing, MI 48909.**

Respondent's failure to submit an answer within 30 days is an admission of all Complaint allegations. If Respondent fails to answer, the Department shall transmit this complaint directly to the Board's DSC to impose a sanction pursuant to MCL 333.16231(9).

Dated: September 12, 2023


By: Patrick Cole, Analyst
Regulation Section
Enforcement Division

Pc/jp.ad